Laboratory News and Research

RSS

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

UCSD announces agreement with PHP to develop UC San Diego Proton Therapy and Research Center

Building on a plan announced in September of 2007, UC San Diego Health Sciences and the Department of Radiation Oncology are pleased to announce an agreement with Proton Health Partners, LLC (PHP) to plan, develop, and operate The UC San Diego Proton Therapy and Research Center.

1 Nov 2010

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Boehringer Ingelheim announced results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load to the lower limit of quantifiable levels in HCV treatment-naïve patients.

1 Nov 2010

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a Phase 1 clinical trial evaluating IMO-2125, a novel immune modulator, in null-responder patients with chronic hepatitis C virus (HCV) infection.

1 Nov 2010

New laboratory-engineered livers could provide solution to donor shortage

Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center have reached an early, but important, milestone in the quest to grow replacement livers in the lab. They are the first to use human liver cells to successfully engineer miniature livers that function - at least in a laboratory setting like human livers. The next step is to see if the livers will continue to function after transplantation in an animal model.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

Researchers generate bioengineered human liver organoid using bioscaffold

Researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine demonstrated the generation of a bioengineered human liver organoid using a liver bioscaffold made from an intact liver extracellular matrix, and filled (seeded) with primary human liver progenitor and endothelial cells.

1 Nov 2010

‘Off the shelf’ new livers from stem cells, glimmer of hope

A researcher team has successfully produced a small-scale version of a human liver in the laboratory using stem cells. This could be a boon for patients waiting for liver transplants although it will take years to perfect the procedure say researchers.

31 Oct 2010

$700,000 worth of adulterated food seized by U.S. Marshals in Georgia

U.S. Marshals, acting under a court order sought by the U.S. Food and Drug Administration, today seized an estimated $700,000 worth of rice and other packaged food products from a rodent-infested warehouse in East Point, Ga. The FDA-regulated food products were stored in a warehouse operated by Sun Hong Kai Holding Inc., which does business as United Food Service.

30 Oct 2010

Researchers enforce to review current regulation on food advertisements

The researchers, in partnership with the Cancer Council, Australia, studied 12,618 food advertisements from 11 countries and found that 67 per cent endorsed unhealthy food. The research builds on a previous study at Liverpool which revealed that children would consume twice as many calories from snacks after watching food adverts compared to after viewing advertising for toys and games.

30 Oct 2010

Summit discusses value, cost-effectiveness of America's investment in wellness and prevention

America's historic investment in wellness and prevention mandated under the Affordable Care Act may not always save money – but it will be worth it.

30 Oct 2010

Presidio to present PPI-461 data for HCV infection at AASLD meeting

Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.

30 Oct 2010

HDL and Virginia governor announce $4.2 million investment for expanding operations

Health Diagnostic Laboratory (HDL, Inc.) and Governor Bob McDonnell have announced an investment of $4.2 million in HDL, Inc. operations, resulting in the creation of 213 new jobs in the City of Richmond. HDL, Inc., located in the Virginia BioTechnology Research Park, will expand its clinical laboratory, diagnostics and clinical trial services, as well as its physician/patient consulting.

30 Oct 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

New findings on protein factories could unravel cell complexities, lead to new antibiotics and disease treatments

A team from The Scripps Research Institute has revealed the first-ever pictures of the formation of cells' "protein factories." In addition to being a major technical feat on its own, the work could open new pathways for development of antibiotics and treatments for diseases tied to errors in ribosome formation. In addition, the techniques developed in the study can now be applied to other complex challenges in the understanding of cellular processes.

30 Oct 2010

AACR announces launch of new journal, Cancer Discovery

The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

30 Oct 2010

Agilent opens new life sciences instruments manufacturing facility in Singapore

Agilent Technologies Inc. today announced the opening of its new life sciences instruments manufacturing facility in Singapore. The facility will produce the company's Liquid Chromatography/Mass Spectrometry (LC/MS) instruments for the global market.

30 Oct 2010

Laboratory News and Research

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

UCSD announces agreement with PHP to develop UC San Diego Proton Therapy and Research Center

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

New laboratory-engineered livers could provide solution to donor shortage

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Researchers generate bioengineered human liver organoid using bioscaffold

‘Off the shelf’ new livers from stem cells, glimmer of hope

$700,000 worth of adulterated food seized by U.S. Marshals in Georgia

Researchers enforce to review current regulation on food advertisements

Summit discusses value, cost-effectiveness of America's investment in wellness and prevention

Presidio to present PPI-461 data for HCV infection at AASLD meeting

HDL and Virginia governor announce $4.2 million investment for expanding operations

CONCERTA improves handwriting performance in children with ADHD: Study

New findings on protein factories could unravel cell complexities, lead to new antibiotics and disease treatments

AACR announces launch of new journal, Cancer Discovery

Agilent opens new life sciences instruments manufacturing facility in Singapore

Lab Diagnostics and Automation - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News